Anti-Human VEGF (Aflibercept Biosimilar)
英诺赛图(InnoCyto)的 Anti-Human VEGF (Aflibercept Biosimilar)(克隆 Aflibercept) 为人源 IgG1-Fc 抗体,靶向 VEGF。提供 1 mg、5 mg、20 mg 规格,目录价 ¥3,390 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 Anti-Human VEGF (Aflibercept Biosimilar)(克隆 Aflibercept) 为人源 IgG1-Fc 抗体,靶向 VEGF。提供 1 mg、5 mg、20 mg 规格,目录价 ¥3,390 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
500401 | 1 mg | ¥3,390
500402 | 5 mg | ¥8,136
500403 | 20 mg | ¥26,442
Product Details
Application|Neutralization, Intracellular Flow cytometry, animal model study
Product Description|Anti-Human VEGF (Aflibercept Biosimilar)
Regulatory Status|RUO
Species specificity|Human
Min Sample Size|1 mg
Storage Conditions|4ºC
Maximal Shelf Life|12 months
See All Formats|Clone Aflibercept
Background Information
Aflibercept is a recombinant fusion protein specifically engineered to act as a decoy receptor for vascular endothelial growth factors (VEGFs). Structurally, the molecule combines the ligand-binding domains of two distinct human receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR), fused to the Fc portion of human immunoglobulin G1 (IgG1). More precisely, Aflibercept contains the extracellular domain 2 of VEGFR-1 and domain 3 of VEGFR-2, which together form a high-affinity binding site for VEGF ligands. The resultant fusion protein has a molecular mass of approximately 115 kilodaltons (kDa) and is produced in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells to ensure proper folding, disulfide bonding, and glycosylation.
The Fc region of Aflibercept serves several critical structural and functional purposes. It provides molecular stability, confers dimerization through disulfide bridges to form a Y-shaped homodimer, and extends the molecule's circulatory half-life via interactions with neonatal Fc receptors (FcRn). The fusion of the VEGF-binding domains to this Fc backbone effectively produces a hybrid receptor that retains the natural ligand-binding specificity of VEGFR molecules while gaining the pharmacokinetic benefits typical of antibodies. Each Aflibercept dimer can bind multiple molecules of VEGF, acting as a soluble trap with high binding affinity in the picomolar range.
Functionally, Aflibercept acts as a potent VEGF antagonist by sequestering VEGF-A, VEGF-B, and placental growth factor (PlGF) before these ligands can interact with their receptors on endothelial cells. By intercepting VEGF signaling, the molecule effectively prevents receptor dimerization and downstream activation of signaling pathways such as MAPK and PI3K-AKT, which are involved in endothelial cell proliferation, survival, and permeability. This molecular sequestration mechanism makes Aflibercept an important biological model for studying angiogenesis regulation, receptor-ligand affinity optimization, and engineered protein-receptor interactions in molecular biology and biochemistry.
Data Sheets
Cat # Size Price Quantity 5004011 mg Add to Cart5004025 mg Add to Cart50040320 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). Anti-Human VEGF (Aflibercept Biosimilar)(500401)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-vegf-aflibercept-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human VEGF (Aflibercept Biosimilar)(500401). 产品目录. https://www.suprotek.cn/products/item/anti-human-vegf-aflibercept-biosimilar.html
@misc{biocsp_item_anti_human_vegf_aflibercept_biosimilar,
title = {Anti-Human VEGF (Aflibercept Biosimilar)(500401)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/anti-human-vegf-aflibercept-biosimilar.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源